𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Doxorubicin, vincristine, and cis-diamminedichloroplatinum (II) therapy in patients with advanced breast cancer

✍ Scribed by Trump, Donald L. ;Ettinger, David S. ;Abeloff, Martin D.

Publisher
John Wiley and Sons
Year
1981
Tongue
English
Weight
151 KB
Volume
9
Category
Article
ISSN
0098-1532

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Preliminary data suggesting synergistic activity of cisplatinum and doxorubicin and the expected poor prognosis of women with breast cancer who progress on treatment with cyclophosphamide, methotrexate and 5‐fluorouracil (CMF), led to a trial of monthly doxorubicin (50 mg/M^2^), vincristine (1.4 mg/M^2^) and cisplatinum (50 mg/M^2^) in such patients. Overall partial response rate to this regimen was 42%; 37% progressed and 21% could not complete two cycles of therapy because of gastrointestinal (three or renal (one) toxicity. This study does not support the use of cisplatinum, 50 mg/M^2^, in combination with doxorubicin and vincristine in patients with breast cancer which has proven refractory to CMF therapy.

πŸ“œ SIMILAR VOLUMES

Concomitant radiation therapy and cis-di
Concomitant radiation therapy and cis-diamminedichloroplatinum (II) in patients with advanced head and neck cancer
✍ Creagan, Edward T. ;Fountain, Karen S. ;Frytak, Stephen ;Desanto, Lawrence W. ;E πŸ“‚ Article πŸ“… 1981 πŸ› John Wiley and Sons 🌐 English βš– 133 KB πŸ‘ 1 views

## Abstract Three patients with locally advanced head and neck squamous cell cancer received concomitant radiation therapy (XRT) and cis‐diamminedichloroplatinum (CDDP). The dose of 6,000 rads was to be administered in two 3,000‐rad courses separated by 3 weeks. The CDDP, 30 mg/m^2^, was to be give

Cis-diamminedichloroplatinum (II) admini
Cis-diamminedichloroplatinum (II) administered by 24-hour infusion in the treatment of patients with advanced upper aerodigestive cancer
✍ Edward T. Creagan; Judith R. O'Fallon; John E. Woods; James N. Ingle; Allan J. S πŸ“‚ Article πŸ“… 1983 πŸ› John Wiley and Sons 🌐 English βš– 364 KB πŸ‘ 2 views

A regression rate of 12% (4/33) among patients with advanced upper aerodigestive carcinomas who received an intravenous regimen of cis-diamminedichloroplatinum, 90 mg/mz/24 hours each three weeks was achieved. The response rate was 13% (3/23) among patients with typical squamous cell carcinoma. Most